- Home
- MGTX vs ENGN Comparison
MGTX vs ENGN Comparison
Compare MGTX & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- ENGN
- Stock Information
- Founded
- MGTX 2015
- ENGN 1999
- Country
- MGTX United States
- ENGN Canada
- Employees
- MGTX N/A
- ENGN N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- ENGN
- Sector
- MGTX Health Care
- ENGN
- Exchange
- MGTX Nasdaq
- ENGN Nasdaq
- Market Cap
- MGTX 302.6M
- ENGN 288.4M
- IPO Year
- MGTX N/A
- ENGN N/A
- Fundamental
- Price
- MGTX $4.18
- ENGN $7.00
- Analyst Decision
- MGTX Strong Buy
- ENGN Strong Buy
- Analyst Count
- MGTX 2
- ENGN 6
- Target Price
- MGTX $22.50
- ENGN $33.67
- AVG Volume (30 Days)
- MGTX 163.7K
- ENGN 74.0K
- Earning Date
- MGTX 11-12-2024
- ENGN 09-10-2024
- Dividend Yield
- MGTX N/A
- ENGN N/A
- EPS Growth
- MGTX N/A
- ENGN N/A
- EPS
- MGTX N/A
- ENGN N/A
- Revenue
- MGTX $8,122,000.00
- ENGN N/A
- Revenue This Year
- MGTX $133.83
- ENGN N/A
- Revenue Next Year
- MGTX $655.34
- ENGN N/A
- P/E Ratio
- MGTX N/A
- ENGN N/A
- Revenue Growth
- MGTX 26.87
- ENGN N/A
- 52 Week Low
- MGTX $3.49
- ENGN $4.94
- 52 Week High
- MGTX $7.60
- ENGN $47.17
- Technical
- Relative Strength Index (RSI)
- MGTX 53.57
- ENGN 53.25
- Support Level
- MGTX $3.86
- ENGN $6.37
- Resistance Level
- MGTX $4.09
- ENGN $6.99
- Average True Range (ATR)
- MGTX 0.18
- ENGN 0.59
- MACD
- MGTX 0.04
- ENGN 0.13
- Stochastic Oscillator
- MGTX 100.00
- ENGN 69.66
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.